SCHEMBL4855232

SCHEMBL4855232

c1ccc2c(c1)CCCSC2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.55
HTR2C P28335 1/20 0.37
TNKS2 Q9H2K2 1/20 0.36
MAOB P27338 4/20 0.35
MAOA P21397 3/20 0.35
CYP2A6 P11509 2/20 0.35
CES1 P23141 1/20 0.34
PNMT P11086 1/20 0.33
CD44 P16070 1/20 0.33
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
DRD4 P21917 2/20 0.32
DRD2 P14416 1/20 0.32
DRD1 P21728 1/20 0.32
DRD5 P21918 1/20 0.32
DRD3 P35462 1/20 0.32
NOS3 P29474 1/20 0.31
BCL2L1 Q07817 1/20 0.31
BAD Q92934 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7064609 0.93 TSHR (0.59) TSHRHTR2CTNKS2MAOBMAOA
SCHEMBL7066238 0.91 TSHR (0.56) TSHRHTR2CTNKS2MAOBMAOA
SCHEMBL10822214 0.87 TSHR (0.41) TSHRHTR2CTNKS2MAOBMAOA
SCHEMBL7062021 0.87 TSHR (0.63) TSHRHTR2CMAOBMAOACYP2A6
SCHEMBL255957 0.85 TSHR (0.46) TSHRHTR2CTNKS2MAOBMAOA
SCHEMBL7065099 0.83 TSHR (0.57) TSHRHTR2CMAOBMAOACYP2A6
Tetrahydrothiophene SCHEMBL17761203 0.80 TSHR (0.68) TSHRHTR2CMAOBMAOACYP2A6
SCHEMBL7062020 0.76 TSHR (0.62) TSHRHTR2CMAOBMAOACYP2A6
SCHEMBL121521 0.76
SCHEMBL29965099 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149357-A1 THERAPEUTIC AGENT FOR NON-MOTOR SYMPTOMS ASSOCIATED WITH PARKINSON'S DISEASE Sumitomo Pharma Co., Ltd. (JP) 2023-05-18 US disclosed
US-20230149357-A1 THERAPEUTIC AGENT FOR NON-MOTOR SYMPTOMS ASSOCIATED WITH PARKINSON'S DISEASE Sumitomo Pharma Co., Ltd. (JP) 2023-05-18 US disclosed
US-11576897-B2 Therapeutic agent for non-motor symptoms associated with Parkinson's disease Sumitomo Pharma Co., Ltd. (JP) 2023-02-14 US disclosed
US-11312668-B2 Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose ABBVIE INC. (US) 2022-04-26 US disclosed
US-20210299099-A1 THERAPEUTIC AGENT FOR NON-MOTOR SYMPTOMS ASSOCIATED WITH PARKINSON'S DISEASE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-09-30 US disclosed
US-11001698-B2 Stabilizer composition BASF SE 2021-05-11 US disclosed
US-20210017100-A1 ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE AbbVie Deutschland GmbH & Co. KG (DE) 2021-01-21 US disclosed
US-10836688-B2 Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose ABBVIE INC. (US) 2020-11-17 US disclosed
US-20200148610-A1 ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE ABBVIE INC. 2020-05-14 US disclosed
US-20200048431-A1 STABILIZER COMPOSITION BASF SE (DE) 2020-02-13 US disclosed
EP-0901787-B1 Stabilized pharmaceutical composition TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2003-05-28 EP disclosed
EP-0952826-B1 IDEBENONE CONTAINING COMBINATION AGENT FOR TREATING ALZHEIMER'S DISEASE TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2001-11-14 EP disclosed
US-6187340-B1 TABLETS WITH COATINGS THAT PROTECT FROM LIGHT TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-02-13 US disclosed
EP-0952826-A1 IDEBENONE CONTAINING COMBINATION AGENT FOR TREATING ALZHEIMER'S DISEASE Takeda Chemical Industries, Ltd. (JP) 1999-11-03 EP disclosed
US-5962535-A SYNERGISTIC MIXTURE OF IDEBENONE AND ACETYLCHOLINESTERASE INHIBITOR TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1999-10-05 US disclosed
EP-0901787-A1 Stabilized pharmaceutical composition Takeda Chemical Industries, Ltd. (JP) 1999-03-17 EP disclosed
WO-1998031356-A1 IDEBENONE CONTAINING COMBINATION AGENT FOR TREATING ALZHEIMER'S DISEASE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-07-23 WO disclosed
EP-0487071-B1 Condensed heterocyclic compounds, their production and use TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1995-07-05 EP disclosed
US-5273974-A Condensed heterocyclic compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1993-12-28 US disclosed
EP-0487071-A1 Condensed heterocyclic compounds, their production and use Takeda Chemical Industries, Ltd. (JP) 1992-05-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11576897-B2 Therapeutic agent for non-motor symptoms associated with Parkinson's disease PARK7, SNCA, ACHE TSHR 926/4885HTR2C 31/4885TNKS2 4294/4885
US-20210017100-A1 ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE LIPA, ALG1, CEL TSHR 4850/4885HTR2C 3446/4885TNKS2 1642/4885
US-20200148610-A1 ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE LIPA, ALG1, CEL TSHR 4850/4885HTR2C 3446/4885TNKS2 1642/4885
US-10836688-B2 Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose LIPA, ALG1, CEL TSHR 4850/4885HTR2C 3446/4885TNKS2 1642/4885
US-20230149357-A1 THERAPEUTIC AGENT FOR NON-MOTOR SYMPTOMS ASSOCIATED WITH PARKINSON'S DISEASE PARK7, SNCA, ACHE TSHR 870/4885HTR2C 26/4885TNKS2 4237/4885
US-20210299099-A1 THERAPEUTIC AGENT FOR NON-MOTOR SYMPTOMS ASSOCIATED WITH PARKINSON'S DISEASE PARK7, SNCA, ACHE TSHR 926/4885HTR2C 31/4885TNKS2 4294/4885
US-11312668-B2 Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose LIPA, ALG1, CEL TSHR 4850/4885HTR2C 3446/4885TNKS2 1642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.